Page 45 - ESHRE2019
P. 45
Patient selection for FSS in EOC is Crucial
• Age <39 ys, / Tumor type: EOC but Clear Cell ? Stage IA, Stage IC ? / Grade I‐II, but III? • FSS did not effect the 5‐year survival in 84–99.5%
• Recurrence rate 8.5–11.3% and Recurrence in contralateral ovary was 4.8%
• FSS did not worsen the prognosis of these patients
• Stage IC and Grade III are important prognostic factors
Tomao F. Critical Reviews in Oncology/Hematology. 2016
• stage IC1 ‐ 50% of recurrences are isolated in the remained ovary • Recurrence rate is 23% in stages I C2 + I C3 disease
• Recurrence for EOC stage 2 and 3 is 38%, is unsafe
40
PRECONGRESS COURSE 11 I VIENNA, AUSTRIA – 23 JUNE 2019 43
